<DOC>
	<DOCNO>NCT03106051</DOCNO>
	<brief_summary>A total approximately 500 patient active psoriatic arthritis estimate 80 100 trial center enrol . Selection center make sponsor 's medical section . To increase quality data reduce distribution data collect , center include enroll least 5 patient . Care take ensure balanced regional distribution . The proposed observation period trial approx . 52 week per patient . Estimated patient enrolment also 52 week . Proposed duration first patient ( FPI ) last patient ( LPO ) thus 24 month .</brief_summary>
	<brief_title>Study Apremilast Use Patients With Psoriatic Arthritic Practice Conditions</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<criteria>The decision treat Otezla® make independently inclusion study Patient age ≥ 18 year Existing diagnosis active psoriatic arthritis At least moderately severe psoriatic arthritis ( Physician 's Global Assessment ( PGA ) scale ≥ 2 ) Insufficient response intolerance previous DiseaseModifying AntiRheumatic Drug ( DMARD ) treatment ( disease modify antirheumatic drug ) A write informed consent statement patient permit data collection , evaluation , storage transfer Pregnancy Hypersensitivity apremilast one ingredient film tablets Other criterion accord summary product characteristic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Psoriatic</keyword>
	<keyword>Observational</keyword>
	<keyword>Apremilast</keyword>
</DOC>